Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desflurane
Drug ID BADD_D00611
Description Desflurane, or I-653, a a volatile anesthetic that is more rapidly cleared and less metabolized than previous inhaled anesthetics such as [methoxyflurane], [sevoflurane], [enflurane], or [isoflurane].[A226390,A39015,A226893]. It was developed in the late 1980s out of a need for a more rapidly acting and rapidly cleared inhaled anesthetic.[A226883,A226888] Desflurane was granted FDA approval on 18 September 1992.[L30285]
Indications and Usage For use as an inhalation agent for induction and/or maintenance of anesthesia for inpatient and outpatient surgery in adults.
Marketing Status Prescription
ATC Code N01AB07
DrugBank ID DB01189
KEGG ID D00546
MeSH ID D000077335
PubChem ID 42113
TTD Drug ID D0H4GN
NDC Product Code 10019-644; 0781-6172; 52584-641; 10019-641; 0404-9961; 57884-0028; 10019-646
Synonyms Desflurane | 1,2,2,2-Tetrafluoroethyl difluoromethyl ether | I 653 | I-653 | I653 | Suprane
Chemical Information
Molecular Formula C3H2F6O
CAS Registry Number 57041-67-5
SMILES C(C(F)(F)F)(OC(F)F)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
NeuritisTransient receptor potential cation channel subfamily A member 1Q8BLA8Not Available25517196
NeuritisTransient receptor potential cation channel subfamily V member 1Q704Y3Not Available25517196
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pruritus23.03.12.001--
Pyrexia08.05.02.003--
Renal failure20.01.03.005--Not Available
Respiratory arrest22.02.01.009--Not Available
Respiratory depression22.02.01.010; 17.02.05.047--Not Available
Respiratory distress22.02.01.012--Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.000206%
Rhabdomyolysis15.05.05.002--
Salivary hypersecretion07.06.01.009--Not Available
Seizure17.12.03.001--
Shock24.06.02.002--Not Available
Tachycardia02.03.02.0070.000788%Not Available
Tachypnoea22.02.01.014--Not Available
Torsade de pointes02.03.04.005--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Ventricular extrasystoles02.03.04.007--Not Available
Ventricular tachycardia02.03.04.0100.000788%
Visual acuity reduced17.17.01.011; 06.02.03.001--
Vomiting07.01.07.003--
White blood cell count increased13.01.06.013--Not Available
Tachyarrhythmia02.03.02.008--Not Available
Ventricular hypokinesia02.04.02.013--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Conjunctival hyperaemia06.04.01.004--Not Available
Lymphatic disorder01.09.01.003--Not Available
Foetor hepaticus09.01.05.006; 07.01.06.026--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Skin burning sensation23.03.03.021; 17.02.06.009--Not Available
Transaminases increased13.03.01.015--Not Available
Haemorrhage24.07.01.002--Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages